Tocilizumab - Wikipedia
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc...
Actemra: Uses, Dosage, Side Effects, MOA - Drugs.com
Aug 22, 2023 · Actemra (tocilizumab) is a FDA approved biological medicine that is given by intravenous infusion or injection under the skin to treat specific patients with COVID-19, rheumatoid arthritis, giant cell arteritis, scleroderma, polyarticular or systemic juvenile idiopathic arthritis, and severe cytokine release syndrome.
Tocilizumab Uses, Side Effects & Warnings - Drugs.com
Jul 23, 2024 · Actemra is used to treat COVID-19, rheumatoid arthritis, systemic juvenile idiopathic arthritis ... You may get infections more easily, even serious or fatal infections. Call your doctor if you have a fever, chills, aches, tiredness, cough, shortness of breath, skin sores, diarrhea, weight loss, or burning when you urinate.
Actemra/RoActemra (tocilizumab) - Roche
Actemra/RoActemra is a first-in-class anti-IL-6 receptor (aIL-6R) therapy. IL-6 is believed to play a key role in activating the inflammatory pathway that contributes to the signs and symptoms of RA and other inflammatory autoimmune conditions.
Subcutaneous Injections for RA | ACTEMRA® (tocilizumab)
ACTEMRA® (tocilizumab) subcutaneous injection instructions and medication guide for Rheumatoid Arthritis (RA) patients. See Full Safety and Boxed Warnings for more information.
Rheumatoid Arthritis (RA) Injections | ACTEMRA® (tocilizumab)
ACTEMRA is a prescription medicine called an interleukin-6 (IL-6) receptor antagonist. ACTEMRA is used: For slowing the rate of decline in lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD) (also known as scleroderma-associated ILD).
ACTEMRA® (tocilizumab) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more...
RoActemra (tocilizumab) An overview of RoActemra and why it is authorised in the EU . What is RoActemra and what is it used for? RoActemra is a medicine used to treat : • adults with severe rheumatoid arthritis that is getting worse who have not been previously treated with a medicine called methotrexate;
RoActemra - patient leaflet, side effects, dosage
RoActemra helps to reduce RA symptoms such as pain and swelling in your joints, and can also improve your performance of daily tasks. RoActemra has been shown to slow the damage to the cartilage and bone of the joints caused by the disease …
RoActemra - European Medicines Agency (EMA)
May 28, 2014 · RoActemra is a medicine used to treat: adults with severe rheumatoid arthritis that is getting worse who have not been previously treated with a medicine called methotrexate; adults with moderate to severe active rheumatoid arthritis whose previous treatments with disease modifying antirheumatic drugs (DMARDs), such as methotrexate or medicines ...
RoActemra 162 mg Solution for Injection in Pre-Filled Syringe
Oct 11, 2024 · The recommended posology is subcutaneous 162 mg once every week in combination with a tapering course of glucocorticoids. RoActemra can be used alone following discontinuation of glucocorticoids. RoActemra monotherapy should not be used for the treatment of acute relapses (see 4.4).
Tocilizumab (Actemra®): Uses & Side Effects - Cleveland Clinic
Tocilizumab treats certain types of arthritis such as rheumatoid arthritis and juvenile idiopathic arthritis. Arthritis causes pain and inflammation in your joints. This medication is an injection that a healthcare provider usually gives to you in a hospital or clinic setting.
Tocilizumab (Actemra) - PMC
Tocilizumab (TCZ), is a recombinant humanized, anti-human monoclonal antibody of the immunoglobulin G1 k subclass directed against soluble and membrane-bound interleukin 6 receptors (IL-6R). 1 It is marketed in the European Union (EU) under the trade name RoActemra and in the United States as Actemra. 2,3 TCZ was first approved in 2005 as an ...
Actemra Side Effects: Common, Severe, Long Term - Drugs.com
Apr 9, 2024 · Along with its needed effects, tocilizumab (the active ingredient contained in Actemra) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention. Check with your doctor immediately if any of the following side effects occur while taking tocilizumab:
Actemra: Side effects, dosage, cost, uses, alternatives, and more
Apr 17, 2022 · Actemra contains the active drug tocilizumab. It belongs to a class of drugs called IL-6 antagonists. (A drug class describes a group of medications that work in the same way.) Actemra works to...
Tocilizumab (Actemra®) - Johns Hopkins Arthritis Center
Tocilizumab is a treatment for adults with moderate to severe rheumatoid arthritis (RA), giant cell arteritis, and polyarticular and systemic juvenile idiopathic arthritis. You must have tried and failed another medication for RA before starting tocilizumab. Tocilizumab blocks a substance called IL-6, known to cause inflammation.
RoActemra 20mg/ml Concentrate for Solution for Infusion
Oct 31, 2024 · RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.
Tocilizumab: A Review in Rheumatoid Arthritis - PubMed
Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra ®), an IL-6 receptor antagonist, are approved (± methotrexate) in numerous countries throughout the world, for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).
RoActemra – Tocilizumab uses, dose and side effects
Jun 25, 2022 · RoActemra has been shown to slow down the damage to cartilage and bone in the joints caused by the disease, and can therefore improve the ability to perform normal daily activities. RoActemra is usually given in combination with another medicine used for …
Tocilizumab | Drugs | BNF | NICE
Tocilizumab (RoActemra®) for the treatment of COVID-19 in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation (March 2023)
Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar ...
Sep 30, 2022 · The MAA includes positive Phase 3 2 data for BIIB800 from the clinical program of a multicenter, multinational, randomized, double-blind, parallel-group, active-control study, designed to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of BIIB800 compared to RoACTEMRA ® in 621 patients with moderate to severe rheumatoid ...